Genmab A/S (GNMSF) Cost of Revenue (2024 - 2026)

Genmab A (GNMSF) has 3 years of Cost of Revenue data on file, last reported at $65.0 million in Q1 2026.

• Quarterly Cost of Revenue rose 54.76% year-over-year to $65.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $363.0 million (up 65.75% YoY) and the FY2025 annual result came in at $238.0 million, up 66.43% from the prior year.
• Cost of Revenue declined to $65.0 million in Q1 2026, from $157.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $157.0 million in Q3 2025 to a low of $27.0 million in Q1 2024.
• A 3-year average of $77.1 million and a median of $65.0 million in 2026 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2025 — Cost of Revenue soared 80.0% — and 2026, when it jumped 54.76%.
• Tracing GNMSF's Cost of Revenue over 3 years: stood at $95.0 million in 2024, then surged by 65.26% to $157.0 million in 2025, then tumbled by 58.6% to $65.0 million in 2026.
• The last three Cost of Revenue figures came in at $65.0 million (Q1 2026), $157.0 million (Q3 2025), and $99.0 million (Q2 2025), per Business Quant data.